Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16800534 | 1.00 | NOS1 (0.43) | NOS1EGLN1SLC6A9GAAHPGD | |
| SCHEMBL1394889 | 0.92 | SLC6A9 (0.42) | EGLN1SLC6A9GAAPDE4BALDH1A1 | |
| SCHEMBL18538871 | 0.91 | NOS1 (0.38) | NOS1EGLN1SLC6A9GAAALDH1A1 | |
| SCHEMBL9205301 | 0.91 | EGLN1 (0.40) | EGLN1SLC6A9GAAHPGDPDE4B | |
| SCHEMBL7869921 | 0.88 | EGLN1 (0.39) | EGLN1SLC6A9PDE4BALDH1A1KMT2A | |
| SCHEMBL12747963 | 0.87 | CYP2C19 (0.41) | GAASMN1; SMN2PDE4BALDH1A1LMNA | |
| SCHEMBL12544369 | 0.87 | CYP2C19 (0.43) | SMN1; SMN2ALDH1A1LMNAKMT2A | |
| SCHEMBL7871400 | 0.86 | ALDH1A1 (0.40) | EGLN1ALDH1A1KMT2A | |
| SCHEMBL20624199 | 0.85 | EGLN1 (0.36) | EGLN1SLC6A9PDE4BKMT2A | |
| SCHEMBL22887713 | 0.84 | SLC6A9 (0.41) | EGLN1SLC6A9GAAPDE4BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | NOS1 2140/4885EGLN1 602/4885SLC6A9 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.